Chester County News and Community Website
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) will present new data from its Phase 2a trial of ATI-2138 in patients with moderate-to-severe atopic dermatitis at the 2026 American Academy …
Aclaris to Present Phase 2a ATI-2138 Data at Dermatology Meeting Read More WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) has completed patient enrollment in its Phase 2 trial of bosakitug in patients with moderate-to-severe atopic dermatitis, marking a development milestone for …
Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis Read More WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) reported its financial results for the fourth quarter and full year of 2025 and provided updates on several clinical-stage drug development programs, …
Aclaris Reports 2025 Financial Results and Clinical Trial Updates Read More WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) said it has initiated a randomized, placebo-controlled Phase 1b proof-of-concept trial of its investigational antibody ATI-052 in patients with asthma, as it …
Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said it will take center stage at two major healthcare investor conferences in February, giving Wall Street and industry watchers a fresh …
Aclaris Lines Up February Spotlight at Major Biotech Investor Conferences Read More WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported striking preclinical results for its experimental oral drug ATI-2138, showing rapid, near-complete, and sustained hair regrowth in a severe mouse model …
Experimental Hair-Loss Drug Sparks Rapid Regrowth in Severe Alopecia Study Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said it has launched a placebo-controlled Phase 1b proof-of-concept trial of ATI-052, an experimental bispecific antibody aimed at treating atopic dermatitis, marking …
Aclaris Pushes New Antibody Into Skin Disease Trial, Eyes Asthma Next Read More WAYNE, PA — Aclaris Therapeutics Inc. (NASDAQ: ACRS) said positive interim data from its first-in-human study of ATI-052 are accelerating the experimental drug’s push toward later-stage trials, signaling what the …
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said it has been added to the Nasdaq Biotechnology Index, a move that places the clinical-stage biopharmaceutical company among a select group …
Aclaris Joins Nasdaq Biotech Index, Marking Milestone for Clinical-Stage Firm Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported third-quarter 2025 financial results and outlined continued progress across its expanding immuno-inflammatory pipeline, emphasizing execution in both oral kinase inhibitors and …
Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 Read More